Merck's Keytruda posts trial win in'messy' early NSCLC realm
As doctors weigh various immunotherapy strategies for the treatment of early-stage non-small cell lung cancer, Merck & Co. | As doctors navigate the "messy" early-stage non-small cell lung cancer landscape with various immunotherapy approaches, Merck & Co. has now unveiled new data that it hopes…#merckco (Source: Reuters: Health)
Source: Reuters: Health - June 5, 2023 Category: Consumer Health News Source Type: news
Thyroid Dysfunction Mild With Cancer Immunotherapy Thyroid Dysfunction Mild With Cancer Immunotherapy
In a real-world study, the prevalence of immune checkpoint inhibitor –associated thyroid dysfunction was greater than 50%, but cases were mild and were even linked to better survival.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 2, 2023 Category: Allergy & Immunology Tags: Diabetes & Endocrinology News Source Type: news
Practice-Changing Data on Low ER+ Breast Tumors? Practice-Changing Data on Low ER+ Breast Tumors?
The immune landscape for low and intermediate estrogen receptor-positive breast tumors appears to mimic that for triple-negative tumors, suggesting a potential role for immunotherapy.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 1, 2023 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Episode 1: When Should You Consider Immunotherapy in Colorectal Cancer? Episode 1: When Should You Consider Immunotherapy in Colorectal Cancer?
Keep up to date on the newest research and clinical application of immunotherapy treatments in colorectal cancer with leading experts Drs Benjamin Schlechter and Marwan Fakih.Medscape (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - June 1, 2023 Category: Radiology Tags: Hematology-Oncology InDiscussion Source Type: news
Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023
Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June. Highlights include new data spanning treatments for lymphoma and hepatocellular carcinoma (HCC):Developing new treatment options for people with blood cancersExtended follow-up data for Columvi ® (glofitamab) of almost two years (20 months) from the pivotal phase II NP30179 study, further investigating the potential of fixed-duration Columvi to provide durable responses in people...
Source: Roche Investor Update - May 26, 2023 Category: Pharmaceuticals Source Type: news
Can automated PET tracer radiosynthesis replace manual methods?
Researchers have developed a new process for automatically synthesizing zirconium-8...Read more on AuntMinnie.comRelated Reading:
Immuno-PET predicts patient response to rituximab therapy
PET tracer reveals dynamics of immunotherapy
Total-body PET/CT tested in COVID-19 patients
Zr-89 tracer helps PET detect subtle prostate cancer lesions
Immuno-PET reveals persistent HIV infection (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 23, 2023 Category: Radiology Source Type: news
Sublingual Immunotherapy Stops Onset and Worsening of Asthma Sublingual Immunotherapy Stops Onset and Worsening of Asthma
The French EfficAPSI study confirmed that sublingual liquid immunotherapy or"desensitization" reduces the risks for asthma onset and the worsening of asthma in patients with allergic rhinitis.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 22, 2023 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news
Chek-Mate for Gliomas
New research may make immunotherapy possible for hard-to-treat brain tumors. (Source: The Scientist)
Source: The Scientist - May 22, 2023 Category: Science Tags: News & Opinion Source Type: news
Insilico Medicine delivers preclinical candidate targeting ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI
Insilico Medicine (Insilico), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that the company has nominated a potentially best-in-class preclinical candidate targeting ENPP1 for cancer immunotherapy and the potential treatment of Hypophosphatasia (HPP).
ENPP1 is an ecto-nucleotide pyrophosphatase that plays an important role in purinergic signaling that regulates immune, cardiovascular, neurological, and hematological system functions. (Source: World Pharma News)
Source: World Pharma News - May 22, 2023 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
DLBCL: Major New Treatment Breakthroughs DLBCL: Major New Treatment Breakthroughs
Recent significant breakthroughs for diffuse large B-cell lymphoma (DLBCL) have come through the use of CAR T-cell and immunotherapies and the FDA approval of polatuzumab for frontline DLBCL.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
New UMD Study Shows How Mesothelioma Can Spread
Researchers at the University of Maryland are getting a better idea of why mesothelioma takes decades to develop in the body.
In a 2023 paper published in the journal Environmental Research, a team of researchers at the University of Maryland found that understanding mesothelioma involves the way immune cells “sense” and interact with particles around them.
The study found the geometry of contaminant particles is more important than mineral composition. This means asbestos causes an immune response once the immune system is exposed to the right shape and size of the particle.
Hijacking the Immune System
Res...
Source: Asbestos and Mesothelioma News - May 17, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
S2 Episode 5: Immunotherapy and Non –Small Cell Lung Cancer S2 Episode 5: Immunotherapy and Non –Small Cell Lung Cancer
Drs Jacob Sands and Stephen V. Liu discuss immunotherapy, biomarkers, next-generation sequencing, shared decision-making, and improving outcomes in the treatment of non –small cell lung cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Immunotherapy Plus Chemo Improves Quality of Life in NSCLC Immunotherapy Plus Chemo Improves Quality of Life in NSCLC
In addition to improving overall survival, the PD-1 inhibitor cemiplimab shows improvements in patient-reported quality-of-life measures.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 17, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
